The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | PD-L1 and TILs predict recurrence in pMMR colon cancer
Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, presents findings from a cohort of patients with colon cancer who underwent surgery and adjuvant chemotherapy, evaluating immune biomarkers including tumor infiltrating lymphocytes (TILs), Immunoscore, and PD-L1 combined positive score (CPS). High TIL status and PD-L1 CPS positivity (≥10) are significantly associated with improved time to recurrence, while PD-L1 CPS negativity correlates with worse outcomes. In a multivariable analysis, age, stage, TILs, and PD-L1 CPS emerge as independent predictors of time to recurrence in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
